ONCOARENDI THERAP ZY-01
Research ONCOARENDI THERAP ZY-01 (1B1) on Bullrun: market cap EUR 33.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1B1
- ExchangeF
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 33.53M
- Financial periodQ1 2025
- RevenuePLN 0
- Net income-PLN 5.18M
- Free cash flowPLN 22.41M
Valuation Snapshot
latest market cap is EUR 33.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2023 | PLN 3.65M | -PLN 28.37M | n/a | n/a | -1.69 | PLN 63.99M | n/a | PLN 100.93M |
| FY2022 | PLN 7.51M | -PLN 35.95M | n/a | n/a | -2.56 | PLN 65.62M | n/a | PLN 80.21M |
| FY2021 | PLN 1.17M | -PLN 13.64M | n/a | n/a | -0.98 | PLN 102.04M | n/a | PLN 115.59M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 33.53M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ONCOARENDI THERAP ZY-01
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ONCOARENDI THERAP ZY-01's market cap?
ONCOARENDI THERAP ZY-01's market capitalization is EUR 33.53M.
What does ONCOARENDI THERAP ZY-01 do?
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH.